Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial

被引：0
|
作者：
Billings, Liana K.
Doshi, Ankur
Gouet, Didier
Oviedo, Alejandra
Rodbard, Helena W.
Tentolouris, Nikolaos
Gron, Randi
Halladin, Natalie
Jodar, Esteban
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
136-OR
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [21] Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)-DUAL IX Trial
    Philis-Tsimikas, Athena
    Billings, Liana
    Busch, Robert S.
    Portillo, Cristobal Morales
    Sahay, Rakesh
    Halladin, Natalie
    Juhl, Ruta Gronskyte
    Harris, Stewart
    DIABETES, 2018, 67
  • [22] Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial
    Rodbard, H. W.
    Bode, B. W.
    Harris, S. B.
    Rose, L.
    Lehmann, L.
    Jarlov, H.
    Thurman, J.
    DIABETIC MEDICINE, 2017, 34 (02) : 189 - 196
  • [23] Comparison of canagliflozin and liraglutide as a replacement for bolus insulin in type 2 diabetes patients well-controlled by basal-bolus insulin
    Kumashiro, N.
    Ando, Y.
    Shigiyama, F.
    Igarashi, H.
    Yoshikawa, F.
    Uchino, H.
    Yoshino, H.
    Miyagi, M.
    Ikehara, K.
    Hirose, T.
    DIABETOLOGIA, 2018, 61 : S126 - S126
  • [24] Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)
    Meneghini, Luigi F.
    Jaeckel, Elmar
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Harvey, John N.
    Begtrup, Kamilla
    Chandarana, Keval
    Vilsboll, Tina
    DIABETES, 2017, 66 : A289 - A289
  • [25] Optimizing Basal-Bolus Therapy in T2D-A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch vs. an Insulin Pen
    Bergenstal, Richard M.
    Peyrot, Mark
    Dreon, Darlene M.
    Aroda, Vanita
    Bailey, Timothy S.
    Brazg, Ronald L.
    Frias, Juan P.
    Johnson, Mary L.
    Klonoff, David C.
    Kruger, Davida F.
    Ramtoola, Shenaz
    Rosenstock, Julio
    Serusclat, Pierre
    Weinstock, Ruth S.
    Naik, Ramachandra G.
    Shearer, David M.
    Zraick, Vivien
    Levy, Brian L.
    DIABETES, 2018, 67
  • [26] Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy
    Abrahamson, Martin J.
    Peters, Anne
    ANNALS OF MEDICINE, 2012, 44 (08) : 836 - 846
  • [27] Cost-effectiveness analysis of insulin degludec/liraglutide (IDegLira) vs other basal insulin intensification strategies in Type 2 diabetes patients uncontrolled on basal insulin in a UK setting
    Davies, M.
    McEwan, P.
    Glah, D.
    Chubb, B.
    Konidaris, G.
    Iversen, P.
    DIABETIC MEDICINE, 2016, 33 : 155 - 155
  • [28] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
  • [29] Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes
    Kerlan, Veronique
    Gouet, Didier
    Marre, Michel
    Renard, Eric
    ANNALES D ENDOCRINOLOGIE, 2013, 74 (5-6) : 487 - 490
  • [30] Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)
    Woerle, H. J.
    Neubacher, D.
    Patel, S.
    von Eynatten, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 : S31 - S32
12345